Metastasis Associated in Colorectal Cancer 1 (MACC1) mRNA Expression Is Enhanced in Sporadic Vestibular Schwannoma and Correlates to Deafness.
Maria BreunKatharina FlockJonas Alexander FeldheimAnja NattmannCamelia M MonoranuPia HerrmannRalf-Ingo ErnestusMario LöhrCarsten HagemannUlrike SteinPublished in: Cancers (2023)
Vestibular schwannoma (VS) are benign cranial nerve sheath tumors of the vestibulocochlear nerve. Their incidence is mostly sporadic, but they can also be associated with NF2 -related schwannomatosis (NF2), a hereditary tumor syndrome. Metastasis associated in colon cancer 1 (MACC1) is known to contribute to angiogenesis, cell growth, invasiveness, cell motility and metastasis of solid malignant cancers. In addition, MACC1 may be associated with nonsyndromic hearing impairment. Therefore, we evaluated whether MACC1 may be involved in the pathogenesis of VS. Sporadic VS, recurrent sporadic VS, NF2-associated VS, recurrent NF2-associated VS and healthy vestibular nerves were analyzed for MACC1 mRNA and protein expression by quantitative polymerase chain reaction and immunohistochemistry. MACC1 expression levels were correlated with the patients' clinical course and symptoms. MACC1 mRNA expression was significantly higher in sporadic VS compared to NF2-associated VS ( p < 0.001). The latter expressed similar MACC1 concentrations as healthy vestibular nerves. Recurrent tumors resembled the MACC1 expression of the primary tumors. MACC1 mRNA expression was significantly correlated with deafness in sporadic VS patients ( p = 0.034). Therefore, MACC1 might be a new molecular marker involved in VS pathogenesis.
Keyphrases
- signaling pathway
- late onset
- lps induced
- end stage renal disease
- amyotrophic lateral sclerosis
- oxidative stress
- ejection fraction
- newly diagnosed
- poor prognosis
- peritoneal dialysis
- inflammatory response
- risk factors
- depressive symptoms
- hearing loss
- single cell
- binding protein
- immune response
- physical activity
- cell proliferation
- cystic fibrosis
- staphylococcus aureus
- cell therapy
- vascular endothelial growth factor